The French company uses a unique approach to active personalized cancer immunotherapy by combining three specific immune players to induce and amplify an immune response, resulting in fewer side effects and a sustainable therapeutic solution for hard-to-treat cancers. Odimma leverages recent advances in immuno-oncology to improve the efficacy of current therapies and believes in the future of precision medicine. With a team of experts and a supportive environment, the company is preparing for its upcoming entry into the clinic.